How to improve R&D productivity: the pharmaceutical industry's grand challenge

  title={How to improve R\&D productivity: the pharmaceutical industry's grand challenge},
  author={Steven M Paul and Daniel S Mytelka and Christopher T. Dunwiddie and Charles C. Persinger and Bernard H. Munos and Stacy R Lindborg and Aaron Leigh Schacht},
  journal={Nature Reviews Drug Discovery},
The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements. In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the number and quality of innovative, cost-effective new medicines… 

Redefining how pharmaceutical innovation gets done

This thesis investigates and improves upon a novel financing technique that has been proposed to facilitate the R&D funding in the bio-pharmaceutical industry, and introduces a new financing paradigm to address the issue of high aggregate costs for these highly curative therapies.

Changing R&D models in research-based pharmaceutical companies

Research-based pharmaceutical companies need to be aware of the key factors, which impact the rate of innovation, R&D cost and probability of success, as they challenge the model of an innovation-driven pharmaceutical industry.

The productivity crisis in pharmaceutical R&D

This study examines the decline of R&D productivity in pharmaceuticals in the past two decades and shows that this decline is associated with an increasing concentration ofR&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biological mechanisms.

Big Data in Pharmaceutical R&D: Creating a Sustainable R&D Engine

With the implementation of ‘Big Data’ initiatives trying to integrate data from disparate data sources and disciplines that are available in life science, the industry has identified a new frontier that might provide the insights needed to turn the ship around and allow the industry to return to sustainable growth.

The productivity crisis in pharmaceutical R &

This decline is associated with an increasing concentration of R&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biological mechanisms and the potential variations in productivity with regard to the regional location of companies are investigated.

Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value

The present study is an attempt to address some major challenges which are: how to increase the overall pace of innovation, how to control the costs and prices of new innovative drugs, and how to improve patients’ timely access to innovative medicines while balancing ‘safety’ concerns.



The Value of Improving the Productivity of the Drug Development Process

Whether faster development times, quicker termination decisions or higher success rates derive from public policy initiatives, better management, or new technologies, the impact on R&D costs can be substantial and result in more innovation and new therapies reaching patients sooner.

Rebuilding the R&D engine in big pharma.

A cultural revolution and a broad transformation of the organization are necessary first steps to rebuilding the R&D engine, the GlaxoSmithKline CEO says.

Modeling Resource Requirements for Pharmaceutical R&D

OVERVIEW: The task of bringing novel pharmaceutical products to market quickly at reasonable cost is daunting. While both pharmaceutical sales and R&D expenses are on the rise, the latter is

Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances

It is found that success probabilities vary substantially across therapeutic categories and are negatively correlated with mean sales by category, which is consistent with a model of dynamic, competitive entry.

The cost of biopharmaceutical R&D: is biotech different?

The results should be viewed with some caution for now given a limited number of biopharmaceutical molecules with data on cash outlays, different therapeutic class distributions for biophARMaceuticals and for pharmaceutical company drugs, and uncertainty about whether recent growth rates in pharmaceutical company costs are different from immediate past growth rates.

Science Business: The Promise, the Reality, and the Future of Biotech

Why has the biotechnology industry failed to perform up to expectations--despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the

Market Watch: Pharma industry performance metrics: 2007–2012E

The analysis focuses on each company’s major prescription drug portfolio (MrDP; the collection of branded drugs each of which is projected to achieve at least us$500 million in annual sales) as a key measure of overall performance as well as forecasted metrics from this peer-group analysis.

The State of Innovation in Drug Development

  • I. Kola
  • Biology, Medicine
    Clinical pharmacology and therapeutics
  • 2008
Because drug development has been stagnant in terms of innovation, there exists huge potential for innovation and failure to innovate drug development will render the “big pharma” model unsustainable.

Can the pharmaceutical industry reduce attrition rates?

The pharmaceutical industry faces considerable challenges, both politically and fiscally, and the fiscal pressures that face the industry from the perspective of R&D are dealt with.

Drug discovery in jeopardy.

Despite striking advances in the biomedical sciences, the flow of new drugs has slowed to a trickle, impairing therapeutic advances as well as the commercial success of drug companies. Reduced